FDA approves costly version of drug for rare disease

The FDA approved Raptor Pharmaceutical's Procysbi to treat nephropathic cystinosis, a rare, inherited pediatric disease. The drug was developed with financing from a foundation started by a patient's parents and is a more easily tolerated version of an existing drug, but Raptor set the price at $250,000.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA